125127-12-0

Basic information

• Product Name: (3aR,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-3-benzyl-4-((tert-butyldiphenylsilyloxy)methyl)tetrahydrofuro[3,4-d]oxazol-2(3H)-one
• Synonyms: (3aR,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-3-benzyl-4-((tert-butyldiphenylsilyloxy)methyl)tetrahydrofuro[3,4-d]oxazol-2(3H)-one
• CAS NO: 125127-12-0
• Molecular Weight: 620.783
• Mol File: 125127-12-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (3aR,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-3-benzyl-4-((tert-butyldiphenylsilyloxy)methyl)tetrahydrofuro[3,4-d]oxazol-2(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: (3aR,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-3-benzyl-4-((tert-butyldiphenylsilyloxy)methyl)tetrahydrofuro[3,4-d]oxazol-2(3H)-one(125127-12-0)
• EPA Substance Registry System: (3aR,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-3-benzyl-4-((tert-butyldiphenylsilyloxy)methyl)tetrahydrofuro[3,4-d]oxazol-2(3H)-one(125127-12-0)

Safety Data

• Hazardous Substances Data: 125127-12-0(Hazardous Substances Data)

Upstream product

• 125084-69-7 9-<2-O-<(benzylamino)carbonyl>-3-bromo-5-O-<(tert-butyl)diphenylsilyl>-3-deoxy-β-D-xylofuranosyl>adenine 
• 119898-65-6 (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((tert-butyldiphenylsilyloxy)methyl)tetrahydrofuran-3,4-diol 
• 58-61-7 adenosine 
• 37731-73-0 (2R,3S,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-bromo-5(hydroxymethyl)tetrahydrofuran-3-ol 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 125084-70-0 9-<2,3-anhydro-5-O-<(tert-butyl)diphenylsilyl>-β-D-ribofuranosyl>adenine 
• 2627-64-7 9-(2,3-anhydro-β-D-ribofuranosyl)adenine 
• 557771-59-2 (2R,3S,4S,5R)-2-(6-amino-9H-purin-9-yl)-4-bromo-5-((tert-butyldiphenylsilyloxy)methyl)tetrahydrofuran-3-yl acetate 
• 3173-56-6 benzyl isothiocyanate 
• 125084-68-6 9-<3-bromo-5-O-<(tert-butyl)diphenylsilyl>-3-deoxy-β-D-xylofuranosyl>adenine 

Downstream Products

• 2504-55-4 3'-amino-3'-deoxyadenosine 
• 53-79-2 puromycin 
• 57183-05-8 tert-butyl [(S)-1-({(2S,3S,4R,5R)-5-[6-(dimethylamino)-9H-purin-9-yl]-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl}amino)-3-(4-methoxyphenyl)-1-oxopropan-2yl]carbamate 
• 58-60-6 3'-amino-3'-deoxy-N⁶,N⁶-dimethyladenosine 
• 420122-71-0 N-(9-((2R,3R,4R,5R)-4-amino-5-(azidomethyl)-3-((tert-butyldimethylsilyl)oxy)tetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide 
• 226917-54-0 2'-O-<(tert-butyl)dimethylsilyl>-3'-deoxy-3'-(hexadecanoylamino)-5'-O-(monomethoxytrityl)-N⁶-<2-(4-nitrophenyl)ethoxycarbonyl>adenosine 
• 226917-53-9 3'-deoxy-3'-(hexadecanoylamino)-5'-O-(monomethoxytrityl)-N⁶-<2-(4-nitrophenyl)ethoxycarbonyl>adenosine 
• 226917-55-1 2'-O-<(tert-butyl)dimethylsilyl>-3'-deoxy-3'-(hexadecanoylamino)-N⁶-<2-(4-nitrophenyl)ethoxycarbonyl>adenosine 
• 226917-51-7 3'-deoxy-3'-(hexadecanoylamino)-N⁶-<2-(4-nitrophenyl)ethoxycarbonyl>adenosine 
• 67313-10-4 9-[3-(benzylamino)-3-deoxy-β-D-ribofuranosyl]adenine 
• 125084-71-1 9-[3-(benzylamino)-3-N,2-O-carbonyl-3-deoxy-β-D-ribofuranosyl]adenine 

Relevant articles and documents

Stereoselective and Divergent Aza-Adenosine and Aza-Guanosine Syntheses from Xylofuranose, the Key Fragments of a STING Cyclic Dinucleotide Agonist

The stereoselective and divergent synthesis of two aza-nucleosides is reported. Starting from xylofuranose 9, aza-adenosine 2 was prepared in 13 steps and 7% overall yield, and aza-guanosine 3 was prepared in 13 steps and 7.8% overall yield. Compared to t

An efficient synthesis of 3′-amino-3′-deoxyguanosine from guanosine

3′-Amino-3′-deoxyguanosine was synthesized from guanosine in eight steps and 58% overall yield. The 2′,3′-diol of 5′-O-[(tert-butyl)diphenylsilyl]-2-N-[(dimethylamino) methylidene]guanosine was reacted with α-acetoxyisobutyryl bromide and treated with 0.5N NH3 in MeOH to yield 9-[2′-O-acetyl-3′-bromo-5′-O-[(tertbutyl) diphenylsilyl]-3′-deoxy-β-D-xylofuranosyl]-2-N- [(dimethylamino)methylidene]guanine, which was reacted with benzyl isocyanate, NaH, and then 3.0N NaOH, and finally with Pd/C (10%) and HCO2NH4 in EtOH/AcOH to afford 3′-amino-3′-deoxyguanosine.

Nucleotides: Part LIX: Synthesis, characterization, and biological activities of new potential antiviral agents: (2'-5')Adenylate trimer analogs containing 3'-deoxy-3'(hexadecanoylamino)adenosine at the 2'-terminus

Based upon 3'-amino-3'-deoxyadenosine (15), its protected 3'- hexadecanoylamino derivative 22 was chosen as starting material for the synthesis of a series of new modified 2'-5'-adenylate trimers 33-36 as potential antiviral agents. All (2'-5')A trimer analogs 33-36 inhibit HIV-1 replication as measured by the inhibition of syncytia formation and inhibition of HIV-1 reverse transcriptase activity. Compound 34 inhibits HIV- 1 reverse transcription by 100% and subsequently inhibits expression of HIV- 1 p24. However, compound 35 acts differently, since it does not inhibit HIV- 1 reverse transcription, HIV-1 integrase, or HIV-1 p24 expression. Therefore, 35 appears to exert its inhibitory effect at a later stage of HIV-1 replication, i.e., the budding process.